Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €33.14 EUR
Change Today -0.65 / -1.91%
Volume 0.0
SGT On Other Exchanges
As of 3:11 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

21823 30th Drive SE

Bothell, WA 98021

United States

Phone: 425-527-4000

Fax: 425-527-4001

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer. ADCETRIS ADCETRIS is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing proprietary technology. The company began to recognize product sales and cost of sales following the accelerated approval of ADCETRIS by the U.S Food and Drug Administration (FDA) in 2011. The company is in the process of collaborating with Takeda Pharmaceutical Company Limited (Takeda) to develop and commercialize ADCETRIS worldwide. Under this collaboration, the company has retained commercial rights for ADCETRIS in the United States and its territories; and in Canada. ADCETRIS was granted conditional marketing authorization in the European Union in 2012 for patients with relapsed Hodgkin lymphoma or relapsed sALCL. The company and Takeda have received marketing authorizations by regulatory authorities in 39 countries, including Japan, Australia, Switzerland, South Korea and Singapore. Other Programs The company has five clinical-stage ADC programs, which consist of SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME, and ASG-15ME. In addition, the company has multiple pre-clinical-stage programs that are being developed as potential candidates for future clinical-stage development. The company also has collaborations for its ADC technology with biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc.; PSMA Development Company LLC, a subsidiary of Progenics Pharmaceuticals Inc.; and Takeda; as well as ADC co-development agreements with Agensys, Inc., an affiliate of Astellas Pharma, Inc., Genmab A/S, and Oxford BioTherapeutics Ltd. ADC Technologies ADCETRIS and its pipeline of monoclonal antibody-based product candidates utilize the ADC technology. ADCs are monoclonal antibodies that are linked to cytotoxic or cell-killing agents. The company’s ADCs utilize monoclonal antibodies that internalize within target cells after binding to a specified cell-surface receptor. The company’s ADCs use proprietary auristatins, which are microtubule disrupting agents, or pyrrolobenzodiazepine (PBD), dimers, which are DNA cross-linkers, as cell-killing agents. ADCETRIS, SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME, and ASG-15ME all utilize its proprietary, auristatin-based or PBD-based ADC technology. The company also has developed a proprietary sugar enhanced antibody (SEA) technology, which is a process to enhance the effector function of monoclonal antibodies to further increase their antitumor activity by selectively reducing sugars in the monoclonal antibodies, specifically fucose. Strategy The company’s strategy is to become a developer and marketer of targeted therapies for cancer. Main elements of its strategy are as follows: successfully execute ADCETRIS commercial plan; expand the therapeutic potential of ADCETRIS; continue to develop other pipeline programs; continue to leverage industry-leading ADC Technology; support future growth of pipeline through internal research efforts and strategic in-licensing; and enter into strategic product collaborations to generate capital and supplement internal resources. Patents For ADCETRIS and related ADC technology, the company’s 27 issued patents would expire between 2014 and 2026 in the United States and Europe. Of these 27 patents, the company owns rights to 16 patents and has licensed rights to 11 patents. For SGN-CD19A and related ADC technology, the company’s 20 issued patents would expire between 2024 and 2029. For SGN-33A and related ADC technology, the company’s one issued patent would expire in 2030. For SGN-LIV1A and related ADC technology, the company’s 23 issued patents would expire between 2014 and 2026. For ASG-22ME and related ADC technology, the company’s 22 issued patents would expire between 2014 and 2026. For ASG-15ME and related ADC technology, the company’s 21 issued patents would expire between 2014 and 2026. History Seattle Genetics, Inc. was founded in 1997. The company was incorporated in Delaware in 1997.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGT:GR €33.14 EUR -0.65

SGT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $8.99 USD -0.11
Genmab A/S kr514.50 DKK -3.00
Insys Therapeutics Inc $60.78 USD -0.21
MorphoSys AG €59.80 EUR -3.01
Pfizer Ltd/India 2,273 INR -13.15
View Industry Companies

Industry Analysis


Industry Average

Valuation SGT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.6x
Price/Book 21.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEATTLE GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at